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Introduction
Histone deacetylases (HDAC) and histone acetyl transferases control acetylation
of histone and non-histone proteins, thereby regulating gene transcription, protein
function, and protein stability. The aberrant expression of HDAC proteins and
Histone deacetylase inhibitors are members of a class of epigeneticdrugs that have proven activity in T-cell malignancies, but little isknown about their efficacy in B-cell lymphomas. Abexinostat is
an orally available hydroxamate-containing histone deacetylase inhibitor
that differs from approved inhibitors; its unique pharmacokinetic profile
and oral dosing schedule, twice daily four hours apart, allows for contin-
uous exposure at concentrations required to efficiently kill tumor cells. In
this phase II study, patients with relapsed/refractory non-Hodgkin lym-
phoma or chronic lymphocytic leukemia received oral abexinostat at 80
mg BID for 14 days of a 21-day cycle and continued until progressive dis-
ease or unacceptable toxicity. A total of 100 patients with B-cell malig-
nancies and T-cell lymphomas were enrolled between October 2011 and
July 2014. All patients received at least one dose of study drug. Primary
reasons for discontinuation included progressive disease (56%) and
adverse events (25%). Grade 3 or over adverse events and any serious
adverse events were reported in 88% and 73% of patients, respectively.
The most frequently reported grade 3 or over treatment-emergent related
adverse events were thrombocytopenia (80%), neutropenia (27%), and
anemia (12%). Among the 87 patients evaluable for efficacy, overall
response rate was 28% (complete response 5%), with highest responses
observed in patients with follicular lymphoma (overall response rate
56%), T-cell lymphoma (overall response rate 40%), and diffuse large B-
cell lymphoma (overall response rate 31%). Further investigation of the
safety and efficacy of abexinostat in follicular lymphoma, T-cell lym-
phoma, and diffuse large B-cell lymphoma implementing a less dose-
intense week-on-week-off schedule is warranted. (Trial registered at:
EudraCT-2009-013691-47)
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ABSTRACT
mutation in the genes encoding HDACs have been linked
to the development of cancers.1-3 The use of HDAC
inhibitors causes hyperacetylation of histone and non-his-
tone proteins, leading to the transcriptional activation of
tumor suppressor genes, as well as genes involved in cell
cycle control, cell division, and apoptosis, resulting in anti-
tumor activity.4 More recently, HDAC inhibitors have also
been shown to exert immunostimulatory effects on cancer
cells. Exposure to HDAC inhibitors was found to up-reg-
ulate natural killer cell-activating ligands, major histocom-
patibility class I and II molecules, proteins involved in anti-
gen presentation, and costimulatory molecules; in colon
cancer cells, treatment with an HDAC inhibitor induced
immunogenic cell death.5 In addition, HDAC inhibitors
can block tumor angiogenesis and indirectly damage DNA
by reducing RAD51 protein and inhibiting DNA repair.4 
Currently, 4 HDAC inhibitors, vorinostat, romidepsin,
belinostat, and panobinostat are approved for the treat-
ment of cutaneous T-cell lymphoma, peripheral T-cell
lymphoma, or multiple myeloma based on their potent
and specific activity.6-10 These agents, along with other
HDAC inhibitors under development, are showing prom-
ising results in B-cell malignancies such as non-Hodgkin
lymphoma (NHL) and chronic lymphocytic leukemia
(CLL),11,12 and solid tumors such as breast cancer.13 The tol-
erability profiles for different HDAC inhibitors vary. The
most commonly reported adverse events include gastroin-
testinal effects (primarily diarrhea, nausea, and vomiting),
constitutional effects (mainly fatigue), hematologic effects
(thrombocytopenia and neutropenia), and cardiac toxici-
ties (QTc prolongation); many of these toxicities were
found to be dose-limiting.14
Abexinostat, a novel, orally available hydroxamate-con-
taining pan-HDAC inhibitor, differs from approved
HDAC inhibitors due to its unique pharmacokinetic pro-
file. Abexinostat was rapidly absorbed following oral
administration, and a maximal plasma concentration was
achieved within 0.5-1 hour; the terminal elimination half-
life was calculated to be approximately four hours.15
Pharmacokinetic modeling was used to determine that the
oral dosing schedule for abexinostat, twice daily four
hours apart, allows for continuous exposure at concentra-
tions required for efficient tumor cell killing while lower-
ing the peak concentrations associated with once-daily
oral administration.16 Abexinostat may, therefore, offer a
more active and potentially less toxic treatment option for
cancer with a wider therapeutic index than other HDAC
inhibitors under development. 
In a phase I/II study of 55 patients with relapsed or
refractory lymphomas, abexinostat was administered on a
1-week-on / 1-week-off schedule, and the recommended
phase II dose was identified as 45 mg/m2 BID (equivalent
to 80 mg BID). At this dose, abexinostat was well-tolerat-
ed with significant clinical activity and highly durable
responses, especially in patients with multiple relapse in
follicular lymphoma (FL).17 With this dosing schedule, the
incidence of grade 3 or over thrombocytopenia was 20%.
Another concurrent phase I study investigated other dos-
ing schedules.15 During phase I of our study, the safety and
efficacy of abexinostat using 3 different dosing schedules
in 35 patients with relapsed or refractory NHL or CLL
were evaluated.15 The recommended phase II dose in this
study was also 45 mg/m2 BID (equivalent to 80 mg BID)
administered on a more dose-intensive 2-weeks-on / 
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Table 1. Patients' baseline characteristics.
Characteristic FL DLBCL MCL T-CL* MZL/ CLL/ LL All 
(n=18) (n=17) (n=16) (n=18) Other (n=16) (n=100)
(n=15)
Age, years 60 63 69 61 69 71 67 
Median (range) (32–83) (38–85) (59–82) (47–78) (52–78) (46–80) (32–85)
Sex, n (%) 
Female 9 (50) 10 (59) 6 (38) 9 (50) 4 (27) 7 (44) 45 (45)
Median BSA, m2 1.9 1.7 1.7 1.8 1.8 1.9 1.8 
(range) (1.3–2.3) (1.4–2.4) (1.4–2.1) (1.5–2.1) (1.5–2.1) (1.4–2.1) (1.3–2.4)
Baseline ECOG performance status, n (%)
0 10 (56) 5 (29) 7 (44) 9 (50) 6 (40) 9 (56) 46 (46)
1 8 (44) 11 (65) 9 (56) 9 (50) 9 (60) 7 (44) 53 (53)
2 0 (0) 1 (6) 0 (0) 0 (0) 0 (0) 0 (0) 1 (1)
Ann Arbor stage, n (%)
I 1 (6) 1 (6) 2 (13) 0 (0) 0 (0)† NA 4 (4)
II 8 (44) 5 (29) 1 (6) 1 (6) 1 (7)† NA 16 (16)
III 2 (11) 5 (29) 1 (6) 4 (22) 4 (27)† NA 16 (16)
IV 7 (39) 6 (35) 12 (75) 13 (72) 5 (33)† NA 43 (43)
Prior treatments
Median 4.5 3 3 2 4 2.5 3
(range) (1–11) (1–10) (1–8) (1–5) (1–7) (1–6) (1–11)
Radiotherapy, n (%) 4 (22) 8 (47) 5 (31) 3 (17) 2 (13) 0 (0) 22 (22)
Median time from diagnosis, months 59.5 18 38 23 90 69 47
(range) (16–156) (5–121) (13–108) (3–99) (18–252) (19–113) (3–252)
BSA: body surface area; CLL: chronic lymphocytic leukemia; DLBCL: diffuse large B-cell lymphoma; ECOG: Eastern Cooperative Oncology Group; FL: follicular lymphoma; LL:
lymphoblastic lymphoma; MCL: mantle cell lymphoma; MZL: marginal zone lymphoma; T-CL: T-cell lymphoma. *Of 18 patients with T-CL treated, 8 presented with angioim-
munoblastic T-cell lymphoma, 6 with peripheral T-cell lymphoma not otherwise characterized, and 4 with cutaneous T-cell lymphoma-mycosis fungoides/Sezary syndrome. †Data
not available for 5 patients.
1-week-off schedule. The use of abexinostat was associat-
ed with a manageable toxicity profile and durable
responses, and showed itself to be particularly active in
patients with relapsed or refractory FL. Here, we report
the safety and efficacy results of phase II of the same
study.
Methods 
This phase II study enrolled patients with relapsed/refractory
NHL or CLL aged 18 years or over with histologically confirmed
NHL [including FL, T-cell lymphoma (T-CL), diffuse large B-cell
lymphoma (DLBCL), mantle cell lymphoma (MCL), marginal
zone lymphoma (MZL), or other subtypes] or immunophenotyp-
ically confirmed CLL. Patients with NHL other than T-CL had
received 2 or more prior lines of standard therapy; patients with T-
CL and CLL had received 1 or more prior treatment. Other eligi-
bility criteria included estimated life expectancy more than 12
weeks, Eastern Cooperative Oncology Group performance status
2 or under, adequate hematologic function (absolute neutrophil
count >1×109/L, hemoglobin ≥8 g/dL, platelet count >100×109/L or
75×109/L in case of bone marrow involvement), adequate renal
function [creatinine <1.5×upper limit of normal (ULN) or creati-
nine clearance ≥50 mL/min], adequate hepatic function (aspartate
amino transferase and alanine aminotransferase <1.5×ULN, total
bilirubin <1.5×ULN), and adequate cardiac functions with potassi-
um levels within normal ranges with or without potassium correc-
tion. Exclusion criteria included allogeneic bone marrow trans-
plant, major surgery within four weeks before the first abexinostat
dose, corticosteroids within ten days or valproic acid within five
days before the first abexinostat dose, prior treatment with HDAC
inhibitor other than valproic acid, concurrent therapeutic anticoag-
ulation by antivitamin K, immunotherapy, chemotherapy
(nitrosoureas within 6 weeks), and radiotherapy within four
weeks before the first abexinostat dose. 
Written informed consent was obtained from all patients before
enrollment. The Institutional Review Board, Research Ethics
Board, and Independent Ethics Committee at each site reviewed
and approved the protocol prior to initiation of the study.
Patients were given oral abexinostat at 80 mg BID four hours
apart for 14 days of a 3-week cycle, and treatment was continued
until progressive disease or unacceptable toxicity. The 80 mg BID
dose, which corresponds to the recommended phase II dose of 45
mg/m2 BID, had been identified in phase I of the study.15 For
patients who could not tolerate abexinostat, treatment was dis-
continued until resolution of the adverse event; treatment was
resumed at a dose of 80 mg BID for five days per week for two
weeks of a 3-week cycle in subsequent cycles. A further dose
Safety and efficacy of abexinostat in NHL and CLL
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Figure 1. Thrombocytopenia with abexinostat treatment. (A) Platelet counts and (B) incidence of grade 3 or over thromoboctyopenia. 
Table 2. Treatment-related adverse events by grade occurring in 5% or
more of patients.
Adverse event, %                                         Any grade         Grades 3/4
Any related adverse event                                         98                           82
Hematologic toxicities                                                 
Thrombocytopenia                                                    87                           80
Neutropenia                                                               34                           27
Anemia                                                                         20                           12
Non-hematologic toxicities                                         
Diarrhea                                                                      42                            3
Nausea                                                                         33                            2
Asthenia                                                                       27                            5
Decreased appetite                                                  23                            0
Vomiting                                                                       17                            0
Fatigue                                                                         11                            0
Epistaxis                                                                       7                             0
Muscle spasms                                                           6                             0
Weight loss                                                                  5                             0
A B
reduction to 60 mg BID for five days per week for two weeks of a
3-week cycle was also permitted, if necessary. 
The primary end point was overall response rate (ORR).
Secondary end points included duration of response, progression-
free survival (PFS), and overall survival. Patients were monitored
for response at the end of every cycle. For patients with NHL,
response was evaluated based on the recommendations of the
International Working Group Revised Response Criteria for
Malignant Lymphomas.18 Patients with CLL were evaluated for
response according to the guidelines of the International
Workshop on Chronic Lymphocytic Leukemia.19 Adverse events
were recorded at each visit using the National Cancer Institute
CTCAE v.3.0 criteria.
This exploratory study enrolled approximately 16 patients per
tumor type. For ORR, 95% exact (Clopper-Pearson) confidence
intervals are provided. The Kaplan-Meier method was used for
time-to-event analyses.
Results
Patients’ baseline characteristics
A total of 100 patients with NHL or CLL were enrolled
in this phase II study between October 2011 and July
2014. Represented histologies included FL (n=18), DLBCL
(n=17), MCL (n=16), T-CL (n=18), MZL and other sub-
types (n=15), and CLL/LL (n=16). Patients' baseline char-
acteristics are presented in Table 1. The median age of the
population was 67 years (range 32-85 years). The median
number of prior therapies was 3 (range 1-11).
Treatment
All patients received at least one dose of study drug. The
median duration of treatment was 2.8 months (range 0.7-
35.4 months). Patients with FL continued abexinostat
treatment longer than other NHL subtypes with a median
treatment duration of 5.6 months. The most common pri-
mary reasons for withdrawal from the study were pro-
gressive disease (56%) and adverse events (25%).
Safety
Treatment-emergent adverse events related to study
drug were reported in 98% of patients, with 82% experi-
encing grade 3 or over events. The most frequently report-
ed grade 3 or over treatment-related AEs were thrombocy-
topenia (80%), neutropenia (27%), and anemia (12%).
The incidence of any grade diarrhea was 42%; however,
only 3% of patients reported grade 3 or over diarrhea
(Table 2). 
Serious AEs were reported in 73% of patients with 70%
reporting grade 3 or over serious AEs. The most common-
ly reported serious AEs included thrombocytopenia
(54%), neutropenia (11%), anemia (7%), and pneumonia
(6%). There were 5 deaths on study, although the investi-
gators of the study did not consider any of them to be
related to treatment.
Because this trial was conducted at a fixed abexinostat
dose, we analyzed whether patients with lower body sur-
face area (BSA), who would have higher drug exposure,
experienced greater toxicities. As expected, grade 3 or over
AEs were more common in patients with a lower BSA
than the median (1.8 m2) when compared with those with
BSA at or above the median (98% vs. 78%). Serious AEs
were also more common in patients with BSA lower than
the median compared with those with BSA at or above
the median BSA (90% vs. 56%).
Adverse events led to dose reductions and treatment
discontinuations in 21% and 29% of patients, respective-
ly. Thrombocytopenia was the most common toxicity
that caused dose reductions, occurring in 17% of patients.
Other adverse events leading to dose reductions included
asthenia (2 patients) and neutropenia, decreased appetite,
V. Ribrag et al.
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Figure 2. Change in
lymph node size.
Waterfall plot of maxi-
mum change from base-
line of the sum of prod-
ucts of the greatest diam-
eters during the treat-
ment phase. CR: com-
plete response; PR: par-
tial response; SD: stable
disease; PD: progressive
disease. *Patient had a 1212% change in target lesion, which falls outside the scale of this figure.
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hypernatremia, and decreased platelet aggregation (each
in 1 patient). Treatment-emergent adverse events that led
to treatment discontinuation in at least 2 patients included
thrombocytopenia (12 patients), neutropenia (3 patients),
anemia (2 patients), and lung infection (2 patients).
Gastrointestinal toxicities resulted in no dose reductions
and only 3 discontinuations resulting from diarrhea, vom-
iting, and rectal hemorrhage in one patient each (Online
Supplementary Table S1). 
Across all tumor types, 4% of patients experienced car-
diac treatment-emergent adverse events, with all events
being reported as grade 1 or 2. One patient experienced
first-degree atrioventricular block and bradycardia.
Cardiac failure, defect in intraventricular conduction, and
nodal arrhythmia were reported in one patient each; none
of these cardiac events were considered serious or related
to treatment. Clinically significant abnormalities in elec-
trocardiogram recordings were reported for 8 patients. 
T-wave inversion, atrial fibrillation, and isolated ventricu-
lar premature beat were each reported in 2 patients; local-
ized ST depression and relevant QTc prolongations were
each reported in one patient.
In comparison to previous experience with abexinostat
administered on a 1-week-on / 1-week-off schedule,17
weekly monitoring for thrombocytopenia showed that
platelet counts fell sharply during the 14 days on abexino-
stat and recovered before the start of the next cycle
(Figure 1). 
Efficacy
At a median follow up of 18 months, 87 patients were
evaluable for efficacy. The 13 patients who did not have
baseline or at least one post-baseline tumor evaluation
were excluded from the efficacy analysis. The ORR across
all tumor types was 28% [95% confidence interval (CI):
19%-38%], with 5% of patients showing complete
responses (CR) and a median duration of response of 8.8
months (range 0.0+ to 27.7+ months) (Table 3 and Figure
2). The highest responses were observed in FL, T-CL, and
DLBCL with ORRs of 56% (95%CI: 30%-80%), 40%
(95%CI: 16%-68%), and 31% (95%CI: 11%-59%),
respectively. Median durations of response of 16.0 months
[95%CI: 3.3-not available (NA)], 11.5 months (95%CI:
1.4-NA), and 1.9 months (95%CI: 0.7-13.6) were observed
in each of these tumor types, respectively. Among patients
with T-CL, responses varied by subtypes with higher
responses observed in patients with angioimmunoblastic
T-cell lymphoma (AITL) with an ORR of 71% (1 CR and
4 PR in 7 evaluable patients) than in patients with periph-
eral T-cell lymphoma not otherwise characterized (ORR
Safety and efficacy of abexinostat in NHL and CLL
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Table 3. Overall response and median duration of response among responders by tumor type.
Tumor type Number ORR, % ORR Median DOR, Median DOR
evaluable (CR, %) 95% CI months (range) 95% CI
FL 16 56 (6) 30–80 16.0 (0.0+–27.7+) 3.3−NA
DLBCL 16 31 (6) 11-59 1.9 (0.7–13.6) 0.7−13.6
MCL 13 15 (8) 2–45 3.6 (2.8–4.3) 2.8−4.3
T-CL 15 40 (7) 16–68 11.5 (1.4–11.8+) 1.4−NA
MZL/Other 13 15 (0) 2–45 8.9 (8.8–9.0) 8.8−9.0
CLL/LL 14 0 (0) 0–23 NA 16.0−NA
Overall 87 28 (5) 19–38 8.8 (0.0+–27.7+) 3.3−13.6
CI: confidence intervals; CLL: chronic lymphocytic leukemia; CR: complete response; DLBCL: diffuse large B-cell lymphoma; DOR: duration of response; FL: follicular lymphoma;
LL: lymphoblastic lymphoma; MCL: mantle cell lymphoma; MZL: marginal zone lymphoma; NA: not available; ORR: overall response rate; T-CL: T-cell lymphoma.  
Figure 3. Progression-free survival
(PFS) in follicular lymphoma (FL), dif-
fuse large B-cell lymphoma (DLBCL),
and T-cell lymphoma (T-CL). mo:
months.
20%; 1 PR) and cutaneous T-cell lymphoma-mycosis fun-
goides/Sezary syndrome (ORR 0%). Median PFS was 10.2
months (95%CI: 2.8-NA) for FL, 5.5 months (95%CI: 2.8-
NA) for T-CL, and 2.8 months (95%CI: 1.4-3.7) for DLBCL
(Figure 3). The PFS for all tumor histologies is shown in
Online Supplementary Figure S1. Median overall survival
was not reached for FL (95%CI: 18.4-NA), and was 17.8
months (95%CI: 11.2-NA) for T-CL and 10.2 months
(95%CI: 4.4-NA) for DLBCL (Figure 4).
Discussion
In this study, we report that the pan-HDAC inhibitor
abexinostat showed an ORR across all tumor types of
28%. Promising response rates were observed in patients
with FL, T-CL, and DLBCL, with ORRs of 56%, 40%, and
31% in each of these NHL subtypes, respectively.
Considering the difficulties involved in cross-trial compar-
isons, the results for abexinostat in FL are consistent with
those of Evens et al., who reported an ORR of 64% with
abexinostat in multiply relapsed disease.17 A median PFS
of 10.2 months was observed for patients with FL in this
study; a median PFS of 20.5 months was reported by
Evens et al. Interestingly, oral vorinostat, which has been
approved for cutaneous T-cell lymphoma, yielded an ORR
of 47% and a median PFS of 15.6 months when tested in
patients with relapsed or refractory FL.20 
Among patients with DLBCL, the ORR of 31%
obtained with abexinostat is similar to the ORR of 28%
recently reported for oral panobinostat in relapsed
DLBCL.21 In other B-cell malignancies, abexinostat was
associated with a modest response rate (15%) among
patients with MCL and MZL. No responses to abexinostat
were observed among patients with relapsed/refractory
CLL, a result that is consistent with reports from other tri-
als of single-agent HDAC inhibitors in this tumor type.22-25
Response to abexinostat in T-CL varied by subtype, with
the highest ORR (71%, including 14% CR) in AITL com-
paring favorably with the ORRs of 30% and 45% reported
for romidepsin26 and belinostat.6
Abexinostat showed a manageable toxicity profile in
various NHL subtypes in this study. The most frequently
occurring non-hematologic events were primarily gas-
trointestinal, and included diarrhea (42%) and nausea
(33%), with most of these events being grade 1 or 2 in
severity. Although cardiac toxicities, especially QTc pro-
longations, are considered a dose-limiting class effect of
HDAC inhibitors,14 the use of abexinostat was associated
with a low incidence of cardiac events (3%), which result-
ed in only one patient discontinuing treatment. These tox-
icities and their rates of occurrence were comparable with
those reported in the phase I study15 and substantially
lower than the phase I/II study by Evens et al., which
reported incidences of nausea and diarrhea of 63% and
50%, respectively, although most of these events were
low grade.17 Hematologic adverse events in this study,
however, were more frequent and generally more severe
than those reported by Evens et al. The incidence of grade
3 or over hematologic adverse events in this study com-
pared to the Evens study were thrombocytopenia (80% vs.
20%) and neutropenia (27% vs. 13%).17 
The difference in the toxicity profiles of abexinostat
between the 2 studies may largely be attributed to the dif-
ferences in dosing schedules used. Abexinostat, when
administered on a 2-weeks-on / 1-week-off schedule, is
associated with higher rates of grade 3 or over hematolog-
ic events. In contrast, the 1-week-on / 1-week-off schedule
was associated with lower rates of high-grade hematolog-
ic toxicities. Platelet counts fell sharply during the 14 days
of abexinostat and recovered during the week patients
were off treatment (Figure 1). In contrast, fluctuations in
platelet counts were less sharp and less prominent with
the 1-week-on / 1-week-off schedule. Given that hemato-
logic toxicities, especially thrombocytopenia, were dose-
limiting in our study, the 1-week-on / 1-week-off dosing
schedule will be explored in future studies. 
In conclusion, this phase II study showed that abexino-
stat is clinically active in patients with relapsed/refractory
NHL, especially in patients with FL, T-CL, and DLBCL,
who exhibited high response rates and durable tumor con-
trol. Abexinostat showed good tolerability during pro-
V. Ribrag et al.
908 haematologica | 2017; 102(5)
Figure 4. Overall survival (OS) in fol-
licular lymphoma (FL), diffuse large
B-cell lymphoma (DLBCL), and T-cell
lymphoma (T-CL). mo: months.
longed drug administration; however, using a less dose-
intense schedule may mitigate the hematologic toxicity.
Abexinostat is currently being tested in a variety of clinical
trial settings, and further examination in FL, T-CL, and
DLBCL is warranted.
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